by101298
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2023 (NCT06462716)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA-dependent protein kinaseINHIBITOR
PRKDC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226986 | Phase 1/Phase 2 (Phase 2) | Dec 16, 2025 | Novartis |
| NCT06524804 | Phase 1/Phase 2 (Phase 2) | May 15, 2024 | Guangzhou Baiyunshan Qixing Pharmaceutical Co Ltd |
| NCT06462716 | Phase 1 | Apr 25, 2023 | Guangzhou Baiyunshan Qixing Pharmaceutical Co Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Baiyunshan Qixing Pharmaceutical Co Ltd | For profit | 2 | 2 | 2 | 2023 |
| Novartis | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1